A Phase 3 interventional study of Antibiotics in Urinary Tract Infection (Diagnosis), sponsored by Megan Bradley. Recruiting at 1 site in United States. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Megan Bradley · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 275 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 57 under way, 2 of them phase 3. Urinary Tract Infections · United States.
Among the 275 studies in Urinary Tract Infections with a site in United States, this one is the 126th largest by planned enrollment of the 225 interventional ones that give a count, is one of 19 that started in 2026, is one of 27 in phase 3, reaches primary completion later than 19 of the 56 other live ones, and was the 268th registered.
808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.
Browse Urinary Tract Infections studies →44 of the 275 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United States
Ages 15–50 · Women only
University of Miami · Sites in United States
Ages 18+ · Women only
GlaxoSmithKline · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
Baylor College of Medicine · Sites in United States
Ages 0 mo–5 mo · Men only
Ohio University · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 65 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
275 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 41 · Phase 3 33 · Phase 4 40
First in 1988; this study’s year is marked. 19 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is below the median of 131 across 564 interventional studies indexed under Urinary Tract Infections.
Median enrollment 100 across the 225 interventional studies, 229 across the 50 observational. Of the 190 that completed or were terminated, 89 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 275 have an industry lead sponsor. The 10 most frequent:
Megan Bradley is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Megan Bradley has 1 study filed under Urinary Tract Infections — fewer than ten, so there is no comparison to draw.
26 of the studies in Urinary Tract Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07686055Phase 3Megan BradleyPrecision Management of Urinary Tract Symptoms in Older Women | 2027-02-01 |
| NCT07947108Good Kitty CoA Clinical Trial to Evaluate the Effects of a Supplement on Urinary Symptoms | 2026-12 |
| NCT06976125University Hospitals Cleveland Medical CenterApplication of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting | 2026-12-01 |
| NCT07453693Bonafide HealthAn Efficacy Study of a Dietary Supplement Drink Mix for Urinary Health Improvement | 2026-12-15 |
| NCT07542834Ohio UniversityUsing Virtual Reality to Improve Medical Training | 2026-12-31 |
Add all 26 to your calendar (.ics) → With an account.
Among the 275 studies in Urinary Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This project aims to improve the diagnosis and management of urinary tract symptoms in older women by comparing three common treatment strategies-empiric antibiotics, urinalysis-guided therapy, and culture-directed care-in a randomized trial. By integrating patient-reported outcomes, laboratory data, the study will identify which patients benefit from antibiotics and which can safely avoid them. Findings will inform precision care strategies and promote antibiotic stewardship while improving symptom outcomes and quality of life in this high-risk population.
Complete a 3-arm randomized pilot trial of either empiric, urinalysis-directed or culture-directed management for UTI symptoms in older women (≥age 65 years old) with a history of recurrent UTI. We will recruit and enroll 90 women with a history of rUTI from the University of Pittsburgh Medical Center - Women's Center for Bladder and Pelvic Health and the Pitt+Me® Research Registry. Once enrolled and randomized, women will be followed for a total of 28 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient reported UTI defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Antibiotic Protocol. For participants in the empiric Rx arm, we will choose an antibiotic with consideration of patient reported allergies, current medications and current Infectious Disease Society of American (IDSA) guidelines. If there is a contraindication to the first antibiotic on the list they will progress to the next option until a suitable selection is achieved.
Drug: Antibiotics
Participants will be directed to refrain from taking antibiotics until results of urine culture are reported, which is expected within 48-72h.
Drug: Antibiotics
Participants will be directed to refrain from taking antibiotics until results of urinalysis reported, which is expected within 12-24 hours
Drug: Antibiotics
Participants will be provided either nitrofurantoin 100 mg oral twice a day for 5 days, trimethoprim/sulfamethoxazole 875/125 oral twice a day for 3 days, fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days or cephalexin 500 mg oral twice a day for 5 days
Clinical Success at 14 Days
Score of \<1 on question 1 (urinary burning),3 (urinary urgency) and 5 (urinary frequency) on Urinary Tract Infection Symptom Assessment at day 14. A lower scale correlates with better symptoms with 0 being no symptoms and 1 being "little" symptoms.
Time frame: 14 days
UTI sequelae
Proportion of those with either ED visit, pyelonephritis or sepsis within 30 days from study start
Time frame: 30 days
Positive urine cultures
Proportion of participants with positive urine cultures
Time frame: 5 days
Change from Baseline in Recurrent Urinary Tract Infection Symptom Scale Score at 14 Days
Score on the Recurrent Urinary Tract Infection Symptom Scale from baseline to 14 day follow-up. This scale has 11 questions with range from 0-10 so the total score is a sum and could range from 0 to 110 (reported as total score). Higher scores represent worse symptoms.
Time frame: 14 days
Antibiotic appropriateness of Current Therapy
Of those that received antibiotics, how many had a positive culture susceptible to the prescribed antibiotic
Time frame: 5 days
Plan to share: No — At this time there is no plan to share IPD.
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.
Of 37 phase 3 interventional studies under Urinary Tract Infections, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 32. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.